Vanguard Asset Management
KNSA icon

Vanguard Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vanguard Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Buy
26,959
+3,536
+15% +$183K ﹤0.01% 1623
2026
Q1 		$1.13M Buy
+23,423
New +$1.04M ﹤0.01% 1733

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vanguard Asset Management's KNSA Position: Q2 2026 in Review

Vanguard Asset Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 15% in Q2 2026, buying an estimated $183K and bringing the position to 26,959 shares worth $1.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1623.

Vanguard Asset Management first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 264 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Vanguard Asset Management held 26,959 shares of Kiniksa Pharmaceuticals worth $1.72M as of Q2 2026.
  • Vanguard Asset Management bought 3,536 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $183K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1623 holding.
  • Vanguard Asset Management first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 264 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.